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1. Introduction
  
 Tuberculosis (TB) is a burden for the world, 
reaching 10 million new cases and 1.2 million deaths 
per year, driving the deadliest contagious disease 
(WHO 2020). The only clinically approved vaccine 
against TB is Bacille Calmette-Guérin (BCG). It gives 
reliable protection against severe TB in children, but 
its efficacy is extremely variable in adults (Fine 1995). 
This limitation urges the need for a new TB vaccine to 
control the spread of the infection. Although there are 
many TB vaccines in the pipeline, their trial phase is 
still overshadowed by unpromising results. Therefore, 
continuous efforts are carried out for developing TB 
vaccines including methods to validate correlates of 
protection in early screening.
 In 2017, a new tuberculosis DNA vaccine, 
pcDNA3.1-rpfD has been successfully constructed 
(Rakhmawati 2017) . It is composed of the pcDNA3.1 
vector and the resuscitation-promoting factor D 
(rpfD) gene. The pcDNA3.1 vector was designed to 
allow replication in bacterial cells and expression 
of the cloned gene in mammalian cells (Invitrogen 
2010). The cloned gene, rpfD encodes a protein that 
plays a role in the resuscitation of Mycobacterium 
tuberculosis (Mukamolova et al. 2002). Rakhmawati 
2017 demonstrated that pcDNA3.1-rpfD induced 
cellular immune responses characterized by the 
production of IL-12 and IFNγ, important cytokines in 
controlling tuberculosis infection. Humoral immune 
response was also successfully induced which was 
defined by the production of IgG anti-RpfD antibodies 
in BALB/c mice, suggesting that it may serve as a 
potent vaccine candidate. Moreover, Pratama 2019 
evinced that the strongest induced IgG subclass was 
IgG2a which bears an important role in facilitating 
M. tuberculosis eradication by complement (Macedo 
et al. 2011) or antibody-dependent cell-mediated 
cytotoxicity (ADCC) (Kips et al. 1985).
 Following the successful completion of in vitro 
study, TB vaccine candidates must enter the extensive 
in vivo study to establish safety, efficacy, and potency. 
Mouse models can be used to aid in the identification 
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of correlates protection through challenge studies 
(Ordway and Orme 2001). Nevertheless, not all 
laboratories support this risky-challenge assay, 
and more so as TB disease progresses, animals may 
experience TB symptoms, pain and will eventually 
die of pulmonary insufficiency. In the effort of 
overcoming this problem, mycobacterial growth 
inhibition assay (MGIA) has been used as an assay 
for down-selecting TB vaccine or ‘gating’ before in 
vivo assay (Tanner 2015). Therefore, only the strong 
candidate is permitted for in vivo challenge and 
thus fulfilling the “protection” in the animal model 
principle. Besides, MGIA has been established to 
produce output that was relevant to the results of 
the challenge assay. Yang et al. 2016 proved that there 
was a significant correlation between the inhibitory 
effect based on the MGIA and the challenge assay, 
supporting the MGIA as an alternative method for 
the challenge assay. In this study, BACTEC MGIT-
based MGIA was adapted for assessment of vaccine 
candidate, pcDNA3.1-rpfD efficacy by measuring 
mycobacterial survival after incubation with PBMCs 
or splenocytes from BALB/c mice. 
2. Materials and Methods
2.1. Isolation and Confirmation of Recombinant 
pcDNA3.1-rpfD Plasmid
 Recombinant pcDNA3.1-rpfD and pcDNA3.1 
plasmid control were isolated from Escherichia coli 
DH5α using Hispeed Plasmid Midi Kit (QIAGEN) 
following manufacturer instruction. The presence of 
the rpfD gene in the isolated plasmid was confirmed 
using conventional PCR with primer F_rpfD and R_
rpfD, or using primer set F_cmV/R_rpfD for correct 
direction of inserted gene (Rakhmawati 2017).
2.2. Mice Immunization
 Eighteen BALB/c mice within aged of 6—8 weeks 
were divided into 3 groups of experiment. Mice 
were immunized intramuscularly with 100 μg/100 
ul pcDNA3.1-rpfD as treatment group, pcDNA3.1 
as negative control group or with 100 ul (equal to 
2-8 x 105 CFU) of BCG SII vaccine intraperitoneally 
(Rakhmawati 2017). All immunization was carried 
out three times within two weeks interval. One 
week after last immunization, mice were terminated 
followed by blood collection and sera separation, 
PBMC and splenocytes isolation. Ethical approval for 
this study was obtained from Komite Etik Penelitian 
Kesehatan FKUI—RSCM, number 616/UN2.F1/ETIK/
PPM.00.02/2020.
2.3. Sera, PBMC and Splenocytes Isolation 
 Blood from terminated mice were collected via 
cardiac puncture, followed by centrifugation for 
sera separation and PBMC isolation using density-
gradient centrifugation with Histopaque® (Sigma) 
(Riedhammer et al. 2014). Mice splenocytes were 
isolated from fresh spleen aseptically. Both PBMC 
and splenocytes were adjusted to 3 x 106 cells in total 
300 ul of RPMI 1640 (Gibco), 2 mM L-glutamine with 
additional 25 mM HEPES for PBMC or 10% of FBS 
(Sigma) for splenocytes.
 
2.4. In Vitro Mycobacterial Growth Inhibition 
Assay
 The following method was adopted from Zelmer et 
al. 2016 and Tanner et al. 2019 with slight modification. 
Prepared splenocytes and PBMC were co-cultured 
with 0.0005 McFarland of Mycobacterium tuberculosis 
H37Rv strain, followed by incubation 37°C with 5% 
CO2 for 96 hours. For PBMC group, 10% of autologous 
sera was added to the co-culture. After incubation, 
co-culture were centrifuged followed by 300 μl 
isolation of supernatant for cytokine analysis and 
obtained pellet were inoculated in to MGIT tube (BD 
Biosciences) and incubated until they were positively 
detected.
2.5. IFNγ Measurement
 IFNγ concentration in co-cultured supernatants 
were measured using mouse IFN gamma ELISA 
kit (Invitrogen) according to the manufacturer's 
instructions. Briefly, the assay was performed 
with incubating 100 μl undiluted supernatant into 
pre-coated wells followed by incubation at room 
temperature (RT) for 1 h. After incubation and washing 
step, biotin conjugate and streptavidin-HRP were 
added subsequently followed also by 1h incubation 
at RT for each reagent and vigorous washing steps. 
Finally, stabilized chromogen substrate was added 
followed by 30 minutes incubation at RT. Reaction 
was stopped by adding stop solution followed 
by absorbance measurement using ELISA reader 
Elx800 BioTek at 450 nm and cytokine concentration 
was calculated in comparison to standard IFNγ 
concentration curve.
2.6. Statistical Analysis
 Statistical Package for the Social Sciences (SPSS) 
was used to perform statistical analysis with p-value 
>0.05.
3. Results
3.1. Isolation and Confirmation of Recombinant 
pcDNA3.1-rpfD Plasmid
Electrophoresis result showed that the isolated 
plasmids were at the length of around 5,428 bp and 
5,893 bp, corresponds to the size of pcDNA3.1 and 
pcDNA3.1-rpfD, respectively (Figure 1a). Furthermore, 
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the PCR product showed a band around 465 bp, 
indicating the rpfD gene was successfully amplified. 
Besides, the PCR product showed that the direction 
of the rpfD gene insertion was correct, as evidenced 
by the presence of a band around 673 bp (Figure 1b).
3.2. Evaluation of Seed Vaccine Protection Based 
on Time to Positivity 
Immune cells (PBMCs or splenocytes) were co-
cultured with M. tuberculosis for 96 hours to give 
immune cells time for delivering their responses. 
The effect was expected since the incubation 
condition was set to 37°C and 5% CO2, which favors 
the growth of mammalian cells. Using the BACTECTM 
MGITTM system, mycobacterial growth in each tube 
was determined by TTP in hours. The higher TTP 
was observed in the test and positive control groups 
compared to the negative control group, as depicted 
in Figure 2. 
Regarding splenocyte co-culture, the mean of 
TTP from the test group (pcDNA3.1-rpfD), negative 
control group (pcDNA3.1), and positive control 
group (BCG) was 323 (±31), 200 (±77), and 283 (±8) 
hours, respectively. The mean of TTP from the test 
group was higher than the negative control group 
(p = 0.047). Likewise, the TTP of the positive control 
group compared to the negative control group (p = 
0.196). As for the test group, it has a higher mean than 
the positive control group (p =  0.081). There was 
no significant difference in TTP from the pcDNA3.1 
group and M. tuberculosis control. As a control, M. 
tuberculosis was incubated in RPMI-S media without 
splenocytes, indicating that the inhibitory effect 




















































Figure 1. Electrophoresis result of (a) pcDNA3.1 and 
pcDNA3.1-rpfD plasmid (b) PCR product using 
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Figure 2. Comparison of MGIA responses expressed in TTP between study groups. (a) TTP of M. tuberculosis co-cultured 
with splenocyte, (b) TTP of M. tuberculosis co-cultured with PBMC
4                                                                                                                                                           Nurfadilah M et al.
A similar trend was observed in the TTP of PBMC 
co-culture. The mean of TTP from the test group 
(pcDNA3.1-rpfD), negative control group (pcDNA3.1), 
and the positive control group (BCG) was 404 (±31), 
355 (±19), and 385 (±14) hours, respectively. The 
mean of TTP from the test group was higher than 
the negative control group (p = 0.024). Likewise, the 
mean TTP of the positive control group compared to 
the negative control group (p = 0.032). Meanwhile, 
the test group has a higher mean than the positive 
control group (p = 0.412).
3.3. Analysis of IFNγ Levels Based on ELISA
To understand the immune response after 
vaccination, we measured the cytokine associated with 
TB infection, IFNγ. The mean of IFNγ concentration 
from splenocyte-M. tuberculosis co-culture (after 
subtraction of the absorbance from the nil control) was 
not significant between the test group, negative control, 
and positive control group (p = 0.387). Likewise, there 
was no significant difference between these treatment 
groups and the splenocyte control group (Figure 3). The 
splenocyte control group was splenocytes from each 
treatment group incubated without M. tuberculosis.
IFNγ was also detected in the supernatant of 
PBMC+M. tuberculosis co-culture. However, no significant 
differences were observed in pcDNA3.1-rpfD, pcDNA3.1, 
and BCG groups. PBMC control group, when compared 
with these treatment groups, also has no significant 



















































































Splenocyte control Splenocyte control
Figure 3. Comparation of IFNγ levels from splenocytes co-culture supernatant after 96 hours incubation. (a) pcDNA3.1—
rpfD, pcDNA3.1, and BCG group have IFNγ levels of 0.05666, 0.05669, and 0.05658 pg/ml respectively, (b) 
splenocytes from mice injected with pcDNA3.1—rpfD, pcDNA3.1, and BCG that cultured without M. tuberculosis 
has IFNγ levels of 0.05677, (c) 0.05668, (d) 0.05665 pg/ml
3.4. Correlation of IFNγ Levels with Time to 
Positivity
The TTP value represented the ability of mammalian 
cells to inhibit the growth of M. tuberculosis in this 
study. The higher the TTP value, the greater the ability 
of mammalian cells to inhibit bacterial growth. The TTP 
value was then correlated with IFNγ levels considering 
that this cytokine was known to play a role in the 
immune response against tuberculosis. Statistical 
analysis showed that the Pearson correlation value 
between IFNγ and TTP of PBMC co-culture was -0.008. 
Meanwhile, the Pearson correlation value between IFNγ 
and TTP from splenocyte co-culture was 0.073.
4. Discussion
 In this study, MGIA was conducted using 
vaccinated mice’s PBMCs or splenocytes co-cultured 
with M. tuberculosis. This procedure was carried 
out on a 48-well plate, which was more favored 
than culturing in a rotating tube as it increased 
mammalian cell viability and cytokine production 
(Jensen et al. 2017; Tanner et al. 2019). The number of 
cells used in this study was 0.0005 McF and 3 x 106 
for mycobacteria and mammalian cells, respectively. 
Regarding the number of mycobacteria, it was 
determined that the inhibition effect of mammalian 
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Figure 4. Comparation of IFNγ levels from PBMC-M. tuberculosis co-culture supernatant after 96 h incubation. (a) 
pcDNA3.1-rpfD, pcDNA3.1, and BCG group have IFNγ levels of 0.05669, 0.05670, and 0.05673 pg/ml respectively, 
(b) PBMC from mice injected with pcDNA3.1—rpfD, pcDNA3.1, and BCG that cultured without M. tuberculosis has 
IFNγ levels of 0.0567, (c) 0.0568, (d) 0.0567 pg/ml
cells toward mycobacteria was still observable along 
with the research time-wise. Besides, the number 
of mycobacteria of 0.0005 McF was known to have 
ten days of TTP (data not shown); Zelmer et al. 2016 
described that the effect of the immune response 
against mycobacteria was expected to be seen. As 
for mammalian cells, despite the more mammalian 
cells, the greater the effect of the immune response 
was, increasing mammalian cells was undesirable. It 
was reported that mammalian cells exceeding 5 x 106 
could cause an event called yellowing culture media 
in 96 hours, leading to unhealthy mammalian cells 
(Painter et al. 2020). 
 The addition of autologous serum to the co-culture 
of the PBMCs ensures the effect of vaccination against 
M. tuberculosis. The addition of serum has been 
shown to enhance the effect of the immune response 
on bacterial growth in human PBMC cultures (Tanner 
et al. 2021). Meanwhile, a study by Pratama 2019 
showed that pcDNA3.1-rpfD was proven to induce 
IgG2a anti-RpfD antibodies in the serum of BALB/c 
mice. The IgG2a subclass is known to play a role 
in the immune response through ADCC (Kips et al. 
1985) and the complement system (Macedo et al. 
2011). After the co-culture period was completed, 
all cells were centrifuged, followed by a re-culture 
process without lysis of mammalian cells because 
the lysis process, with water, PBS-Tween, saponins, 
SDS, or without lysis did not affect the re-culture 
results (Tanner et al. 2019). 
 The output of MGIA is the ability to inhibit the 
growth of M. tuberculosis, which can be expressed in 
TTP. The use of the BACTECTM MGITTM system has the 
advantage of detecting bacterial growth faster and 
providing more accurate growth measurement results 
(Pfyffer et al. 1997; Brennan et al. 2017). Although 
co-culture observations with a microscope at 400x 
magnification did not show any morphological 
differences (data not shown), statistical analysis of 
TTP values in splenocyte and PBMC cultures showed 
significant differences between the treatment 
groups (Figure 2). These results indicate that PBMC 
cells from mice immunized with pcDNA3.1-rpfD or 
with BCG could inhibit the growth of tuberculosis. 
Control of mammalian cells constituting PBMCs 
and splenocytes without M. tuberculosis cells was 
also carried out. The TTP measurement of control 
mammalian cells was negative for the use of oxygen 
in the MGIT tube within 42 days (data not shown). 
These results indicated that the positive growth 
results in the MGIT tube, by decreasing oxygen 
levels in the tube, are indeed due to the growth 
of M. tuberculosis and not due to the presence of 
mammalian cells. These results also confirm the 
research by Tanner et al. 2019 that BACTEC MGIT-
based MGIA can be performed without mammalian 
cell lysis.
 Indeed, the PBMC and spleen are composed of 
immune cells that have a role in inhibiting the growth 
of M. tuberculosis. Dendritic cells (DCs) that respond to 
the RpfD antigen from the injection site may migrate 
to the spleen or lymph nodes. The expression of RpfD 
protein has been demonstrated by Rakhmawati 2017 
that anti-RpfD antibodies were detected in the serum 
of mice injected with pcDNA3.1-rpfD. These DCs are 
thought to present antigen to CD8+ T cells followed by 
differentiation into effector cells and finally leaving 
the spleen (Bronte and Pittet 2013). Effector T cells 
can be taken up and participate in inhibiting bacterial 
growth during the co-culture period. In addition, T 
cells can differentiate into memory cells (Abbas et al. 
2018). When induced with M. tuberculosis during co-
culture, these T cells can respond to the presence of 
bacteria.
 Growth inhibition of M. tuberculosis also occurs 
with monocyte response. Antigens released by 
transfected cells may be captured by APCs, processed 
via the endocytosis system, and then presented to 
CD4+ T (Gurunathan et al. 2000; Klutzer and Weiner 
2008; Li and Petrovsky 2016). These CD4+ T cells 
can differentiate into Th1 in the presence of the IL-
12 cytokine (Abbas et al. 2018). Regarding IL-12, it 
was determined that immunization with pcDNA3.1-
rpfD triggered higher levels of IL-12 compared to the 
control group (Rakhmawati 2017). Furthermore, Th1 
cells produce IFNγ, which plays a role in macrophage 
activation (Abbas et al. 2018). The growth of M. 
tuberculosis in co-culture was prevented in the test 
group, pcDNA3.1-rpfD, assuming that activated 
macrophages were taken up and participated in 
inactivity during the co-culture period. 
 Considering the importance of IFNγ in eradicating 
M. tuberculosis, in this study, IFNγ levels were 
measured using ELISA. The results showed that IFNγ 
was detected in each treatment group. However, IFNγ 
levels were not significantly different between the 
immunized group and the negative control group. 
These results may arise due to injection treatment 
in the negative control group with pcDNA3.1. This 
plasmid does not express the RpfD protein, but 
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possible that it can express other proteins such as 
the neomycin resistance gene, which is part of the 
pcDNA3.1 plasmid (Invitrogen 2010). Neomycin 
resistance gene expression might triggered the 
production of IFNγ. Thus, in the negative control, 
IFNγ was also detected by ELISA even though the 
production of IFNγ was triggered by a different cause. 
Furthermore, statistical differences could not be 
detected when comparing IFNγ levels between the 
pcDNA3.1-rpfD and the negative control groups. This 
limitation can be avoided by adding a naive BALB/c 
mouse not given injection treatment in subsequent 
studies. This naive control group can be used as a 
reference to normalize the data (Yang et al. 2016). 
On the other hand, the measurement time may have 
contributed to the absence of differences in levels of 
IFNγ. In this study, the measurement of IFNγ levels 
was carried out on the 4th day. It is possible that at 
that time, the levels of IFNγ in culture are no longer 
sensitive to make a difference at that point. The 
MGIA study that found differences in IFNγ levels was 
carried out by Marsay et al. 2013 by measuring the 
level of IFNγ gene expression at 12 hours. 
 In this study, it was found that there was no 
relationship between IFNγ levels and the ability to 
inhibit the growth of M. tuberculosis, as indicated by 
Pearson correlation analysis. In line with previous 
reports by Hoft et al. 2002; Kampmann et al. 2004; 
Fletcher et al. 2013; Joosten et al. 2018; Tanner et al. 
2019. This phenomenon is due to the complexity 
of the immune response to M. tuberculosis, which 
involves various cytokines likes IL-12, IL-18, IL-23, 
and TNFα, which were not measured in this study. In 
addition, the killing of M. tuberculosis itself is carried 
out by effector cells such as macrophages, CD4+ T 
cells, and CD8+ T cells, not by cytokines (Crevel et al. 
2002; Schaaf and Zumla 2009). Therefore, in addition 
to IFNγ, it is preferred to measure the number or 
ratio of effector cells in co-culture (Silver et al. 
1998). These findings suggest that complex immune 
mechanisms exerted by other cytokines and their 
interactions with immune cells may be responsible 
for the inhibition. Therefore, the MGIA results can be 
used as a complete method to assess vaccine potency 
to accompany cellular response analysis. 
 In conclusion, this study provides evidence that 
pcDNA3.1-rpfD conferred protection against M. 
tuberculosis as reflected by longer TTP compared 
to the negative control. As this vaccine candidate 
yielding greater potential, it may be feasible to 
proceed to the in vivo challenge assay with animal 
models. Moreover, the result was supported by the 
positive control group, BCG which has already known 
as an agent in preventing tuberculosis infection. Even 
though IFNγ levels did not show any correlation with 
TTP, this finding was in line with previous evidence. 
Suggesting that MGIA may serve as an additional 
method for evaluating vaccine candidates.
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